• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在亨廷顿舞蹈病的器官型切片培养模型中,单链Fv胞内抗体对突变蛋白的作用提供了功能保护。

A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease.

作者信息

Murphy Robert C, Messer Anne

机构信息

Wadsworth Center/David Axelrod Institute, New York State Department of Health and Department of Biomedical Sciences, University at Albany, P.O. Box 22002, Albany, NY 12201-2002, USA.

出版信息

Brain Res Mol Brain Res. 2004 Feb 5;121(1-2):141-5. doi: 10.1016/j.molbrainres.2003.11.011.

DOI:10.1016/j.molbrainres.2003.11.011
PMID:14969746
Abstract

Huntington's disease (HD) is a progressive, hereditary, neurodegenerative disorder caused by an expanded polyglutamine tract in huntingtin protein, leading to misfolding and abnormal protein-protein interactions. Reducing the initial misfolding should lead to decreased pathogenesis. We show that malonate stress increases the number of dead or dying cells when organotypic slice cultures are transduced to express pathological-length huntingtin fragments. Co-transfected anti-HD single-chain Fv (sFv) intrabodies can reverse this HD-specific increase in malonate-induced morbidity.

摘要

亨廷顿舞蹈症(HD)是一种进行性、遗传性神经退行性疾病,由亨廷顿蛋白中多聚谷氨酰胺序列的扩展引起,导致蛋白质错误折叠和异常的蛋白质-蛋白质相互作用。减少初始错误折叠应能降低发病机制。我们发现,当器官型脑片培养物被转导以表达病理长度的亨廷顿片段时,丙二酸应激会增加死亡或濒死细胞的数量。共转染的抗HD单链Fv(sFv)胞内抗体可以逆转丙二酸诱导的HD特异性发病率增加。

相似文献

1
A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease.在亨廷顿舞蹈病的器官型切片培养模型中,单链Fv胞内抗体对突变蛋白的作用提供了功能保护。
Brain Res Mol Brain Res. 2004 Feb 5;121(1-2):141-5. doi: 10.1016/j.molbrainres.2003.11.011.
2
Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.人源单链Fv抗体在亨廷顿舞蹈症细胞模型中可原位对抗亨廷顿蛋白聚集。
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4764-9. doi: 10.1073/pnas.071058398.
3
Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.人源单链Fv抗体对果蝇亨廷顿病病理学的抑制作用
Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11563-8. doi: 10.1073/pnas.0505321102. Epub 2005 Aug 1.
4
A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease.一种人源单链Fv胞内抗体在亨廷顿舞蹈病的纹状体模型中优先靶向氨基末端亨廷顿蛋白片段。
Neurobiol Dis. 2005 Jun-Jul;19(1-2):47-56. doi: 10.1016/j.nbd.2004.11.003.
5
Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.亨廷顿舞蹈病转基因小鼠模型中对丙二酸酯诱导的纹状体细胞死亡的部分抗性取决于年龄和CAG重复长度。
J Neurochem. 2001 Aug;78(4):694-703. doi: 10.1046/j.1471-4159.2001.00482.x.
6
Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.基于腺病毒载体的亨廷顿病体外神经元细胞模型,具有人类疾病样的差异聚集和变性。
J Gene Med. 2012 Jul;14(7):468-81. doi: 10.1002/jgm.2641.
7
Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.Sp1和TAFII130转录活性在早期亨廷顿舞蹈病中受到破坏。
Science. 2002 Jun 21;296(5576):2238-43. doi: 10.1126/science.1072613. Epub 2002 May 2.
8
Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity.与突变型亨廷顿蛋白富含脯氨酸结构域结合的胞内抗体可提高其周转率并降低神经毒性。
J Neurosci. 2008 Sep 3;28(36):9013-20. doi: 10.1523/JNEUROSCI.2747-08.2008.
9
AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease.腺相关病毒介导的转录因子 XBP1s 向纹状体的传递减少了亨廷顿病小鼠模型中突变型亨廷顿蛋白的聚集。
Biochem Biophys Res Commun. 2012 Apr 13;420(3):558-63. doi: 10.1016/j.bbrc.2012.03.033. Epub 2012 Mar 16.
10
Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment.突变型亨廷顿蛋白在体内与多聚谷氨酰胺片段不同的上下文依赖构象形成复合物。
Neurobiol Dis. 1999 Oct;6(5):364-75. doi: 10.1006/nbdi.1999.0260.

引用本文的文献

1
Emerging Therapies for Huntington's Disease - Focus on N-Terminal Huntingtin and Huntingtin Exon 1.亨廷顿病的新兴疗法——聚焦于N端亨廷顿蛋白和亨廷顿蛋白外显子1
Biologics. 2022 Sep 30;16:141-160. doi: 10.2147/BTT.S270657. eCollection 2022.
2
Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers.抗体片段作为阐明结构-毒性关系以及用于诊断/治疗神经毒性淀粉样寡聚体的靶向治疗的工具。
Int J Mol Sci. 2020 Nov 24;21(23):8920. doi: 10.3390/ijms21238920.
3
POSCAbilities: The Application of the Prion Organotypic Slice Culture Assay to Neurodegenerative Disease Research.
POSCAbilities:Prion 器官型切片培养测定在神经退行性疾病研究中的应用。
Biomolecules. 2020 Jul 20;10(7):1079. doi: 10.3390/biom10071079.
4
Engineered Extracellular Vesicles/Exosomes as a New Tool against Neurodegenerative Diseases.工程化细胞外囊泡/外泌体作为对抗神经退行性疾病的新工具。
Pharmaceutics. 2020 Jun 9;12(6):529. doi: 10.3390/pharmaceutics12060529.
5
A novel ex vivo Huntington's disease model for studying GABAergic neurons and cell grafts by laser microdissection.通过激光显微切割研究 GABA 能神经元和细胞移植物的新型亨廷顿病体外模型。
PLoS One. 2018 Mar 5;13(3):e0193409. doi: 10.1371/journal.pone.0193409. eCollection 2018.
6
Induced Pluripotent HD Monkey Stem Cells Derived Neural Cells for Drug Discovery.诱导多能性 HD 猴干细胞衍生的神经细胞用于药物发现。
SLAS Discov. 2017 Jul;22(6):696-705. doi: 10.1177/2472555216685044. Epub 2016 Dec 27.
7
Recombinant Antibody Fragments for Neurodegenerative Diseases.用于神经退行性疾病的重组抗体片段
Curr Neuropharmacol. 2017;15(5):779-788. doi: 10.2174/1570159X01666160930121647.
8
The P42 peptide and Peptide-based therapies for Huntington's disease.用于治疗亨廷顿舞蹈症的P42肽及基于肽的疗法。
Orphanet J Rare Dis. 2016 Mar 17;11:24. doi: 10.1186/s13023-016-0405-3.
9
Modulating the Amyloidogenesis of α-Synuclein.调节α-突触核蛋白的淀粉样蛋白生成
Curr Neuropharmacol. 2016;14(3):226-37. doi: 10.2174/1570159x13666151030103153.
10
Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington's disease.复合物的差异性核定位可能是亨廷顿舞蹈病体内抗体药物疗效的基础。
Protein Eng Des Sel. 2014 Oct;27(10):359-63. doi: 10.1093/protein/gzu041.